Nutraceuticals. Efficacy, Safety and Toxicity. Edition No. 2

Table of Contents

Section I. Applications of nutraceuticals in common diseases and disorders
1. Nutraceuticals in central nervous system diseases: potential mechanisms of neuroprotection
2. Prevention of neurodegenerative disorders by nutraceuticals
3. Cognitive effects of nutraceuticals
4. Nutraceuticals in anxiety and stress
5. Countering cardiovascular diseases with nutraceuticals
6. Nutraceuticals for diabetes and glucose balance
7. Role of nutraceuticals in respiratory and allied diseases
8. Nutraceuticals in hepatic diseases
9. Nutraceuticals in renal diseases
10. Nutraceuticals in gastrointestinal disorders
11. Nutraceuticals in reproductive and developmental disorders
12. Nutraceuticals in ophthalmic diseases
13. Nutraceuticals in dermal diseases
14. Nutraceuticals in arthritis
15. Nutraceuticals in sports activities and fatigue
16. Role of nutraceuticals as adaptogens
17. Nutraceuticals for weight loss
18. Nutraceuticals in cancer prevention
19. Application of "nano� nutraceuticals in medicine
Section II. Models and mechanisms in evaluation of nutraceuticals
20. The biology of nutrients: genetic and molecular principles
21. Genomic and proteomic mechanisms and models in toxicity and safety evaluation of nutraceuticals
22. Transcriptomic profiling for safety and toxicity evaluation of
nutraceuticals
23. Target identification and polypharmacology of nutraceuticals
24. Systems pharmacology investigation of mechanism of action of nutraceuticals
25. Noninvasive in vivo optical imaging models for safety and toxicity testing
26. Flow cytometry and light-scattering techniques in evaluation of nutraceuticals
27. Zebrafish as a model system to evaluate the safety and toxicity of nutraceuticals
28. Caenorhabditis elegans: an elegant model organism for evaluating the neuroprotective and neurotherapeutic potential of nutraceuticals
29. Alternative in vitro models for safety and toxicity evaluation of nutraceuticals
30. Mitochondria as a target for safety and toxicity evaluation of nutraceuticals
31. Oxidative stress and excitotoxicity: antioxidants from nutraceuticals
Section III. Common nutraceuticals
32. Caffeine: an evaluation of the safety database
33. Biological activities and potential nanotechnological delivery of resveratrol
34. Melatonin: a safe nutraceutical and clinical agent
35. Standardized turmeric and curcumin
36. Curcuminoid-metal complexes for oxidative stress
37. Fenugreek: multiple health benefits
38. Cannabis sativa: an overview
39. Cannabidiol safety
40. St John's wort (Hypericum perforatum L)
41. Green tea
42. Green coffee beans
43. Quercetin
44. German chamomile
45. Isoflavones: toxicological aspects and efficacy�
46. Propolis
47. Bee products as nutraceuticals to nutraceuticals for bees
48. Ginkgo biloba
49. Chinese ginseng
50. Ashwagandha: multiple health benefits
51. Astaxanthin: health benefits and toxicity
52. Thymoquinone
53. Glucosinolates
54. Organosulfur compounds as nutraceuticals
55. Arginine and citrulline as nutraceuticals: efficacy and safety in diseases
56. Neem Extract
57. Spirulina
58. Garcinia cambogia
59. Vitamin E TPGS and its applications in nutraceuticals
60. Role of transferrin: an iron-binding protein in health and diseases
61. Glutamine supplementation: hope, hype, or stay tuned?
62. What to do with placenta after birth: is it a waste?
63. Chitin, chitosan, and their derivatives
Section IV. Prebiotics and probiotics
64. Prebiotics: safety and toxicity considerations
65. Probiotics: safety and toxicity considerations
66. Synbiotics: safety and toxicity considerations
Section V. Nutraceuticals in veterinary medicine
67. Nutraceuticals in animal health and diseases
Section VI. Toxicity and toxic interactions
68. Toxic contamination of nutraceuticals and food ingredients
69. Nutraceuticals and adverse outcome pathways
70. Interactions between nutraceuticals/nutrients and nutrients and therapeutic drugs
71. Genotoxicity evaluation of nutraceuticals
Section VII. Regulatory aspects
72. The regulatory framework for nutraceuticals: North America
73. Evaluation and regulation of food supplements: European perspective
74. Regulatory guidelines for nutraceuticals in India: an overview
75. Regulatory aspects of nutraceuticals: Chinese perspective
76. Uses and regulation of nutraceuticals: Australia and New Zealand
77. Regulatory aspects of nutraceuticals: Japanese perspective
78. Nutraceuticals: the Turkish perspective

Authors

Ramesh C Gupta Professor and Head, Toxicology Department, Breathitt Veterinary Center, Murray State University, Hopkinsville, KY, USA. Dr. Ramesh C. Gupta, Professor & Head of Toxicology Department at Murray State university, is engaged in experimental brain research in relation to Alzheimer's disease (AD) and pesticide toxicity. He has delivered lectures in Australia, Italy, Japan, Germany, France, Switzerland, Spain, Czech Republic, China, South Korea, and Sweden. He served the panels of NIH, CDC, NIOSH, and NAS. He has >350 publications to his credit, including seven major books with Elsevier: (1) Toxicology of Organophosphate and Carbamate Compounds, (2) Veterinary Toxicology: Basic and Clinical Principles, (3) Handbook of Toxicology of Chemical Warfare Agents, (4) Anticholinesterase Pesticides: Metabolism, Neurotoxicity, and Epidemiology, (5) Reproductive and Developmental Toxicology, (6) Biomarkers in Toxicology and (7) Neutraceuticals. He is recipient of Murray State University's distinguished researcher award of the year-2006. He is a diplomate of American Board of Toxicology, and fellow of American College of Toxicology, American College of Nutrition, and Academy of Toxicological Sciences. Rajiv Lall Founder and CEO, ProbioticSmart, LLC and Vets Plus, Inc.. Mr. Rajiv Lall is the Founder and CEO of ProbioticSmart, LLC, a novel nutraceutical ingredients development company based on research and evidence-based science and Vets Plus, Inc., an international leader in the animal health industry. He graduated with two Masters degrees, the first in Botany from his native country of India, and the second in Pharmacognosy/Medicinal Chemistry from the University of Minnesota. His research focused on identifying, analyzing, and extracting natural ingredients from plants and plant tissue cultures that provide natural health and medicinal properties, as well as on enzymes in relation to cancer cells through animal cell cultures. Mr. Lall started his career in the human health food industry with an emphasis on probiotics. His relentless drive continues to champion both human and animal health through scientific research and the development of nutritional products and pharmaceuticals, and through these efforts he has obtained various patents and developed several hundred products. His company, Vets Plus, Inc. is a research and science-based product development company with a strong quality and manufacturing platform to support partners in Europe and around the world. Recent awards include the Pet Age Icon Award (2015), NASC Visibility Award (2015), and Menomonie Area Chamber of Commerce Business of the Year Award (2015). Vets Plus Inc. was also nominated for Wisconsin Manufacturer of the Year in 2015. In support of the animal health industry, Mr. Lall is now Founder and CEO of Noble Pharma, LLC, a pharmaceutical company in Menomonie, Wisconsin. Mr. Lall and his wife Swati are involved in philanthropic efforts and through that they have developed the Raj and Swati Lall Microbiology Laboratory at the University of Wisconsin-Stout in support of future scientists and business leaders and the community in Menomonie, Wisconsin. Ajay Srivastava Chief Scientific Officer, Vets Plus Inc.; Adjunct Faculty Member, University of Wisconsin-Stout, Menomonie, USA. Dr. Ajay Srivastava is Chief Scientific Officer at Vets Plus Inc. and serves as an adjunct Faculty member at University of Wisconsin-Stout, Menomonie, US. He is specialized in preclinical and clinical product development and nutraceutical research. After receiving his BS in Biological Sciences, Dr. Srivastava earned his DVM from the School of Veterinary Medicine at GB Pant University of Agriculture and Technology, India, before pursuing his MS in Pharmacology. He completed his PhD in Neuropharmacology from All India Institute of Medical Sciences, New Delhi. After his post-doctoral training in preclinical drug development in neurological disorders, Dr. Srivastava became Senior Research Scientist of the Anticonvulsant Drug Development Program at the University of Utah, where he developed a novel animal model of pharmacoresistant epilepsy to screen potential antiepileptic drugs. He is one of the pioneer researchers who discovered the role of nutraceuticals resveratrol and melatonin in epilepsy. Dr. Srivastava has chaired various scientific sessions in AVMA and WVC meetings and has published several research articles in peer reviewed journals. He has contributed chapters in textbooks on epilepsy, toxicology and nutraceuticals.